This newsletter presents you the following key sessions:
1. Podcast with Prof. Dr. Sara Hurvitz about subgroup analyses from the randomised phase III
DESTINY-Breast03 study
2. Consistent benefit of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab
in high-risk early stage triple negative breast cancer
3. HR+/HER2- metastatic breast cancer patients with ESR1 mutations benefit from early switch to fulvestrant
plus palbociclib
4. Pyrotinib plus capecitabine improves survival in pre-treated patients with HER2+ breast cancer
5. The prognostic and predictive value of intrinsic subtype across the MONALEESA-2, -3, and -7 studies